Treatment of Confirmed Pertussis with Positive Bordetella Test
Treat this patient with a macrolide antibiotic: azithromycin for 5 days or clarithromycin for 7 days are preferred over erythromycin for 14 days due to better tolerability and equal efficacy. 1
Primary Treatment Recommendations
According to CDC guidelines, macrolide antibiotics are the cornerstone of pertussis treatment for patients over 1 month of age 1. The key decision points are:
First-Line Macrolide Options (Age >1 month):
- Azithromycin: 5-day course (preferred for convenience and tolerability)
- Clarithromycin: 7-day course (equally effective)
- Erythromycin: 14-day course (effective but more side effects, poor adherence)
All three macrolides are equally effective at eradicating B. pertussis from the nasopharynx 1, but azithromycin and clarithromycin have significant advantages: they require fewer daily doses (1-2 times daily vs 4 times daily), shorter treatment duration (5-7 days vs 14 days), and cause fewer gastrointestinal side effects that improve patient adherence 1.
Alternative Agent (Age >2 months):
- Trimethoprim-sulfamethoxazole (TMP-SMX): 7-day course if macrolides are contraindicated 1
Critical Timing Consideration
The patient is at 2 weeks of cough—treatment should still be initiated despite being in the later phase of illness. While macrolides administered early in the course can reduce symptom duration and severity, the primary benefit at this stage is reducing communicability and preventing transmission to others 1. The patient will remain culture-positive and contagious without treatment, with 80-90% spontaneously clearing B. pertussis only after 3-4 weeks from cough onset 1.
Important Clinical Caveats
Drug Interactions to Consider:
- Erythromycin and clarithromycin (but NOT azithromycin) inhibit the cytochrome P450 enzyme system (CYP3A subclass) and can interact with other medications metabolized by this pathway 1
- If the patient is on other medications, azithromycin may be the safer choice
Expected Clinical Course:
Antibiotics will NOT significantly alter the clinical course at 2 weeks into illness 2. The post-tussive emesis, paroxysmal cough, and other symptoms will likely persist despite treatment because the toxin-mediated damage is already established 1. Set realistic expectations with the patient that treatment primarily prevents spread to others rather than providing immediate symptom relief.
Contact Prophylaxis:
Identify and treat close contacts (household members, those with face-to-face exposure) with the same antibiotic regimens to prevent secondary cases, especially if there are infants <12 months, pregnant women in third trimester, or other high-risk individuals in the household 1.
Emerging Resistance Concerns
Be aware of macrolide-resistant B. pertussis, particularly if the patient has recent travel to or contact with individuals from mainland China 3, 4. In certain regions of China, 70-100% of recent isolates are macrolide-resistant 4. If macrolide resistance is suspected or confirmed:
- TMP-SMX for 7 days is the established alternative 1
- Recent evidence suggests levofloxacin (5-7 days) shows comparable effectiveness to TMP-SMX with favorable safety profile 5
- Beta-lactams (piperacillin, cefoperazone-sulbactam, meropenem) show good in vitro activity and may be considered for macrolide-resistant strains 6
However, resistance remains rare outside China, so standard macrolide therapy is appropriate for most cases 4.
Practical Implementation
For this patient, prescribe:
- Azithromycin: Day 1: 10 mg/kg (max 500 mg), Days 2-5: 5 mg/kg once daily (max 250 mg)
- OR Clarithromycin: 15 mg/kg/day divided twice daily for 7 days (max 1 g/day)
Counsel the patient that they remain contagious until completing 5 days of appropriate antibiotic therapy and should avoid contact with infants and high-risk individuals during this period 1.